Want to see TSE:MDNA full AI Analyst Report?
Top Page
Medicenna Therapeutics Corp
(TSX:MDNA)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.44
▼(-6.17% Downside)
Action:Reiterated
Date:10/20/26
The score is primarily weighed down by weak financial performance (no revenue, large losses, and sustained cash burn with a shrinking equity base), which increases financing/dilution risk. Technicals are neutral overall but still reflect a longer-term downtrend versus the 200-day average. Valuation is constrained by negative earnings (negative P/E) and no dividend support.
Positive Factors
Engineered Cytokine Platform
Medicenna’s engineered cytokine platform is designed to address the therapeutic limitations of native interleukins by targeting activity and tolerability. If clinical development validates these intended benefits, the platform could support multiple oncology and immune-disease programs rather than relying on a single candidate.
Negative Factors
No Product Revenue
Medicenna has no reported product revenue because its programs remain in clinical development and no approved commercial product is identified. Without recurring sales, the business cannot yet fund operations through customers, leaving progress dependent on clinical execution and access to external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Engineered Cytokine Platform
Medicenna’s engineered cytokine platform is designed to address the therapeutic limitations of native interleukins by targeting activity and tolerability. If clinical development validates these intended benefits, the platform could support multiple oncology and immune-disease programs rather than relying on a single candidate.
Read all positive factors
Medicenna Therapeutics Corp (MDNA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$35.32M
Dividend YieldN/A
Average Volume (3M)43.42K
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue GrowthN/A
EPS Growth-33.27%
CountryCA
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding77,617,340
10 Day Avg. Volume46,407
30 Day Avg. Volume43,416
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)21.45
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.18
Revenue Forecast (FY)N/A
Medicenna Therapeutics Corp Business Overview & Revenue Model
Company Description
Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) empowered cy...
How the Company Makes Money
Medicenna Therapeutics does not appear to generate recurring revenue from product sales because its programs are in clinical development and it does not have an approved commercial product. As a result, the company’s funding has primarily been sup...
Medicenna Therapeutics Corp Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -75.00K | -77.00K | -55.00K | -5.00K | -5.00K | -38.00K |
| EBITDA | -22.99M | -23.64M | -12.98M | -18.67M | -16.30M | -22.54M |
| Net Income | -18.56M | -18.41M | -11.80M | -25.47M | 1.55M | -22.65M |
Balance Sheet | ||||||
| Total Assets | 8.25M | 8.45M | 28.38M | 19.13M | 36.45M | 23.46M |
| Cash, Cash Equivalents and Short-Term Investments | 5.69M | 6.25M | 24.84M | 16.98M | 33.60M | 20.54M |
| Total Debt | 104.00K | 119.00K | 168.00K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 6.58M | 5.97M | 9.29M | 13.94M | 6.96M | 2.62M |
| Stockholders Equity | 1.67M | 2.48M | 19.09M | 5.19M | 29.49M | 20.84M |
Cash Flow | ||||||
| Free Cash Flow | -14.33M | 0.00 | -16.52M | -16.26M | -12.66M | -23.58M |
| Operating Cash Flow | -18.81M | -17.92M | -16.49M | -16.26M | -12.66M | -23.58M |
| Investing Cash Flow | 2.00K | 2.00K | -33.00K | 0.00 | -13.05M | 10.05M |
| Financing Cash Flow | 3.82M | -19.00K | 23.49M | 0.00 | 24.76M | 3.88M |
Medicenna Therapeutics Corp Technical Analysis
Positive
0.47
Price Trends
0.43
Positive
0.41
Positive
0.56
Negative
Market Momentum
<0.01
Negative
58.82
Neutral
92.98
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDNA, the sentiment is Positive. The current price of 0.47 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.43, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.82 is Neutral, neither overbought nor oversold. The STOCH value of 92.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MDNA.
Medicenna Therapeutics Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | C$122.35M | 28.16 | 15.04% | 6.94% | 4.11% | 88.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | C$35.32M | -2.07 | -360.29% | ― | ― | -33.27% | |
44 Neutral | C$56.38M | -19.53 | 74.79% | ― | ― | -15.53% | |
42 Neutral | C$202.40M | -3.45 | -72.67% | ― | ― | -6.00% |
* Healthcare Sector Average
TSE:MDNA
Medicenna Therapeutics Corp
0.46
-1.03
-69.26%
TSE:MSCL
Satellos Bioscience
9.54
0.30
3.25%
TSE:ARCH
Arch Biopartners
0.83
-0.16
-16.16%
TSE:COV
Covalon Technologies
4.43
2.29
107.01%
TSE:METX
ME Therapeutics Holdings, Inc.
1.10
-3.90
-78.00%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Medicenna Therapeutics Corp Corporate Events
Business Operations and StrategyProduct-Related Announcements
Medicenna’s MDNA209 Shows Strong CD122 Blockade and Survival Gains in Autoimmune Preclinical Models
Positive
Oct 26, 2026
Medicenna Therapeutics reported new preclinical data on MDNA209, its engineered CD122 superantagonist, showing tight binding to CD122 and blockade of IL-2 and IL-15 signaling, pathways that drive autoimmune disease. In human immune-cell studies, M...
Business Operations and StrategyProduct-Related Announcements
Medicenna to Showcase CD122 Superantagonist MDNA209 Data at Paris Immunotherapy Meeting
Positive
Oct 22, 2026
Medicenna Therapeutics will present new preclinical data on MDNA209, a long-acting CD122 superantagonist engineered to block IL-2 and IL-15 signaling, at The Promises of Treg and Interleukin-2 Therapies Conference in Paris. By targeting CD122, MDN...
Business Operations and StrategyShareholder MeetingsStock Split
Medicenna Shareholders Back Board, Auditor and Potential Share Consolidation Plan
Positive
Oct 1, 2026
Medicenna shareholders elected all management-nominated directors with more than 97% support and approved the re-appointment of MNP LLP as auditor at the company’s annual general and special meeting. Roughly 31.82% of outstanding common shar...
Business Operations and StrategyProduct-Related Announcements
Medicenna to Present New Bizaxofusp Survival Data in Recurrent Glioblastoma at SNO 2026
Positive
Sep 24, 2026
Medicenna Therapeutics said new survival data for its lead candidate bizaxofusp in unresectable, IDH-wildtype recurrent glioblastoma has been selected for an oral presentation at the 2026 Society for Neuro-Oncology annual meeting in Philadelphia. ...
Business Operations and Strategy
Medicenna to Spotlight Superkine Pipeline at H.C. Wainwright Global Investment Conference
Positive
Sep 3, 2026
Medicenna Therapeutics Corp., listed on the TSX and OTCQX, operates as a clinical-stage immunotherapy innovator focused on engineered cytokine therapies known as Superkines for cancer and immune-related diseases. Its pipeline features bizaxofusp f...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Medicenna Advances Superkine Pipeline With New Data and Regulatory Plans
Positive
Aug 14, 2026
Medicenna reported fiscal 2027 first-quarter results and said cash and cash equivalents stood at $5.7 million at June 30, 2026, slightly down from $6.3 million three months earlier. The company reiterated its focus on advancing its Superkine pipel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.